Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 9/20 | 0.47 |
| ▸ | CTSS | P25774 | 5/20 | 0.46 |
| ▸ | CTSL | P07711 | 4/20 | 0.46 |
| ▸ | CTSB | P07858 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | KYNU | Q16719 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209279 | 1.00 | SYK (0.49) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL2707957 | 0.92 | PPARA (0.49) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL14985678 | 0.92 | PPARA (0.49) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL203729 | 0.92 | PPARA (0.49) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL2345022 | 0.89 | SYK (0.51) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL2345024 | 0.89 | SYK (0.51) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL4313271 | 0.88 | FOLH1 (0.52) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL4313267 | 0.88 | FOLH1 (0.52) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL2578492 | 0.85 | SYK (0.54) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL7215282 | 0.85 | SYK (0.54) | SYKCTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079683-B1 | DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-7781487-B2 | Di-fluoro containing compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20080214676-A1 | DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY, INC. (US) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214676-A1 | DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CTSF, CTSZ, CTSS | SYK 2283/4885CTSK 8/4885CTSS 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.